This $5 Stock Could Hit $50 by January This “Musk Target” to 10X By January 1st?

Six days after AstraZeneca’s roughly $10 billion approach leaked, Rhythm Pharmaceuticals (RYTM) is still trading well below the top of the offer range. That discount is not an oversight. It is the market’s real-time probability estimate, and it deserves a closer read than the headline numbers suggest.

AstraZeneca’s non-binding offer values Rhythm at up to $134 a share, including milestone payments. Shares closed at $110.68 on the day the news broke, up 28%. As of November 10, the stock has not closed the spread. That gap, roughly $23 to the top of the range, reflects two distinct risks: deal completion and price sufficiency.

On the second risk, the market has already weighed in. Analysts at Jefferies, Leerink Partners, and William Blair all suggested a bidding war could develop, arguing Rhythm is unlikely to settle for AstraZeneca’s current pitch. Then, two days after the initial reports, that view found confirmation. On November 6, Rhythm shares climbed an additional 4.2% following news of a second potential bidder entering the fray.

The strategic logic for any acquirer is not abstract. In March 2026, the FDA expanded the use of Rhythm’s therapy Imcivree for acquired hypothalamic obesity, a rare form of obesity caused by hypothalamic injury or impairment. That label expansion transformed what was a narrow ultra-rare play into something with a materially larger addressable market. Third quarter 2026 net product revenue from global Imcivree sales hit $92.1 million, a 29% increase from the prior quarter. Commercial momentum at that pace commands a premium.

The acquisition would be pursued through AstraZeneca’s rare-disease unit Alexion, which AstraZeneca agreed to buy for $39 billion in December 2020 and completed in July 2021 to expand beyond its core oncology and biopharmaceutical franchises. While Rhythm’s therapies target rare genetic forms of obesity rather than the broader weight-loss market, a deal would give AstraZeneca an established commercial presence in the fast-growing field while expanding its rare-disease portfolio. That is a different value proposition than chasing Novo Nordisk and Eli Lilly in GLP-1.

William Blair anticipated Imcivree could reach $3.6 billion in annual sales by 2032, not including the potential for an approval in Prader-Willi syndrome. Rhythm is planning a Phase 3 trial for that rare disease later this year. A successful Prader-Willi readout would revalue the pipeline substantially, which is exactly what milestone-linked deal structures are designed to price.

Milestone-linked deal structures are only one way a pipeline revaluation can move a stock. A single external ruling can reprice a pharmaceutical company’s entire litigation overhang in a single session.

The practical question for traders is positioning around the spread. The gap between the $110.68 close and the top offer price leaves room for the market to price in both the odds of a completed deal and the possibility of a higher bid. Neither company has confirmed the approach or its terms. Until a definitive agreement surfaces, that uncertainty keeps the stock from fully closing on $134.

Watch for two things: whether the second bidder is identified, and whether AstraZeneca hardens its non-binding proposal into a signed term sheet. Either development compresses the spread fast. The absence of either keeps it wide, and the trade stays open.